Ironwood Pharma (IRWD) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
May 5, 2022 7:00 AM EDTLINZESS® (Iinaclotide) prescription demand growth increased 11% year-over-year; LINZESS U.S. net sales of $232 million, an increase of 8% year-over-year
Total revenue of $98 million; U.S. LINZESS collaboration revenue of $94 million
GAAP net income of $39 million and adjusted EBITDA of $58 million; ended Q1 2022 with $593 million in cash and cash equivalents
BOSTON--(BUSINESS... More
